Article
Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.
Haematologica - 1 Sept 2021
Oppliger Leibundgut Elisabeth, Haubitz Monika, Burington Bart, Ottmann Oliver G, Spitzer Gary, Odenike Olatoyosi, McDevitt Michael A, Röth Alexander, Snyder David S, Baerlocher Gabriela M
Abstract excerpt
In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies. Significant molecular responses were achieved within 3-6 months in 81% of patients with phenotypic driver mutations in JAK2, CALR and MPL. Here, we investigated the dynamics of additional somatic mutations in response to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.